Enjaymo
What Enjaymo is used for
Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Enjaymo
- Active substance
- sutimlimab
- Disease area
- Hemolysis; Anemia, Hemolytic, Autoimmune
- Medicine group
- Immunosuppressants
- ATC code
- L04AJ04
- Marketing authorisation holder
- Recordati Rare Diseases
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Enjaymo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Enjaymo used for?
Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
What is the active substance in Enjaymo?
Enjaymo contains sutimlimab.
Who makes Enjaymo?
The EU marketing authorisation holder is Recordati Rare Diseases.
Is Enjaymo an orphan medicine?
Yes. Enjaymo is designated an orphan medicine in the EU, for a rare disease (Hemolysis; Anemia, Hemolytic, Autoimmune).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU